Outlook for VTE treatment and prophylaxis market

Driven primarily by the launches and strong uptake of oral anticoagulants, the combined markets for drugs used in the treatment and prophylaxis of venous thromboembolism will experience moderate growth over the next decade, increasing from $3.4 billion in 2010 to $4.7 billion in 2020 in the leading markets of the USA, France, Germany, Italy, Spain, the UK and Japan, according to a new report from health care advisory firm Decision Resources.

DR’s Pharmacor advisory service titled Venous Thromboembolism finds that German drugmaker Bayer (BAY: DE) and Johnson & Johnson (NYSE: JNJ) unit Janssen’s Xarelto (rivaroxaban) will emerge as the sales-leading new therapy in the combined VTE markets and its closest competitor will be US drug major Bristol-Myers Squibb (NYSE: BMY) and Pfizer’s (NYSE: PFE) Eliquis (apixaban).

Negative clinical trials in prophylaxis